|
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not
intended to be used as a source of information on on healthcare or medicines.
The web pages are not kept up to date and are for demonstration purposes only.
For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines
or the package leaflet of your medicine. For up-to-date information on other
healthcare topics, please consult the relevant reliable sources or an healthcare
expert, such as a physician etc.
|
BACK TO LIST |
European Patient Summary
|
|
|
|||||||||||||||||||
Problem list
| Condition | Onset Date / Period | Status |
|---|---|---|
| Hyperlipidemia | 14-Apr-2024 | active |
| Chronic sinusitis | 31-Jan-2020 | active |
| Hyperglycemia | 22-Feb-2015 | active |
| Metabolic syndrome X | 16-Feb-2014 | active |
| Anemia | 16-Feb-2014 | active |
| Hypertriglyceridemia | 11-Aug-2013 | active |
| Type 2 diabetes mellitus | 03-Jun-2012 | active |
| Acute bacterial sinusitis | 22-Dec-2019 - 03-May-2020 | inactive |
Medication list
| Medication | Since | Form | Dosage | Reason |
|---|---|---|---|---|
| Simvastatin 10 mg oral tablet | 2025-05-05 | - | 1 tablet (10 mg) by mouth once daily | Hyperlipidemia |
| Ibuprofen 400 mg oral tablet | 2025-04-20 | - | 1 tablet (400 mg) every 6 to 8 hours as needed | - |
| Metformin hydrochloride 500 mg prolonged-release oral tablet | 2025-04-20 | - | 1 tablet (500 mg) once daily | Diabetes mellitus type 2 (disorder) |
| Acetaminophen 300 mg and hydrocodone bitartrate 5 mg oral tablet | 2014-03-21 | - | 1 tablet (300 mg/5 mg) every 4 to 6 hours as needed | - |
Immunizations list
| Vaccine | Date |
|---|---|
| Influenza virus antigen only vaccine product | 20-Apr-2025 |
| Hepatitis A virus antigen only vaccine product | 03-Apr-2022 |
| Clostridium tetani toxoid antigen adsorbed only vaccine product | 03-Apr-2022 |
| SARS-CoV-2 mRNA vaccine | 02-May-2021 |
Procedure History list
| Procedure | Date | Reason |
|---|---|---|
| Depression screening | 09-Feb-2020 | - |
| Medication reconciliation | 09-Feb-2020 | - |
| Assessment of health and social care needs | 09-Feb-2020 | - |
| Assessment of anxiety | 09-Feb-2020 | - |
Allergies and Intolerances
| No known allergies or intolerances |
Care Plan
| Active Planned Care / Goals | Start Date | Reason |
|---|---|---|
| Hyperlipidemia clinical management plan | 05-May-2024 | Hyperlipidemia (disorder) |
|
||
| Therapy | 21-Mar-2014 | - |
| Diabetes self management plan | 03-Jun-2012 | Diabetes mellitus type 2 (disorder) |
|
Vital Signs
| Vital Signs | 2025-04-20 | 2024-04-14 |
|---|---|---|
| Body Height | 171.3 cm | 171.3 cm |
| Pain severity - 0-10 verbal numeric rating [Score] - Reported | 3 {score} | 2 {score} |
| Body Weight | 81 kg | 81 kg |
| Body mass index (BMI) [Ratio] | 27.6 kg/m2 | 27.6 kg/m2 |
| Heart rate | 77 /min | 73 /min |
| Respiratory rate | 13 /min | 14 /min |
| Blood pressure panel with all children optional | 72 mm[Hg] | 73 mm[Hg] |
Relevant diagnostic tests/laboratory data
| Recent Lab Observations | 05-MAY-2025 | Reference Range | Unit |
|---|---|---|---|
| Glucose [Mass/volume] in Blood | 158.5 H | 70 - 100 | mg/dL |
| Urea nitrogen [Mass/volume] in Blood | 8.7 | 7 - 20 | mg/dL |
| Creatinine [Mass/volume] in Blood | 3.5 H | 0.6 - 1.2 | mg/dL |
| Calcium [Mass/volume] in Blood | 10.0 | 8.5 - 10.5 | mg/dL |
| Sodium [Moles/volume] in Blood | 137.5 | 135 - 145 | mmol/L |
| Potassium [Moles/volume] in Blood | 4.1 | 3.5 - 5.0 | mmol/L |
| Chloride [Moles/volume] in Blood | 101.9 | 98 - 107 | mmol/L |
| Carbon dioxide, total [Moles/volume] in Blood | 26.8 | 22 - 29 | mmol/L |
| Protein [Mass/volume] in Serum or Plasma | 7.7 | 6.0 - 8.3 | g/dL |
| Albumin [Mass/volume] in Serum or Plasma | 4.4 | 3.5 - 5.2 | g/dL |
| Globulin [Mass/volume] in Serum by calculation | 2.8 L | 25 - 35 | g/L |
| Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | 0.2 - 1.2 | mg/dL |
| Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 76.3 | 39 - 117 | U/L |
| Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22.4 | 10 - 40 | U/L |
| Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 14.3 | 10 - 40 | U/L |
| Cholesterol [Mass/volume] in Serum or Plasma | 158.7 | 125 - 200 | mg/dL |
| Triglyceride [Mass/volume] in Serum or Plasma | 153.9 H | 0 - 150 | mg/dL |
| Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay | 141.9 H | 0 - 100 | mg/dL |
| Cholesterol in HDL [Mass/volume] in Serum or Plasma | 47.4 | 40 - 60 | mg/dL |
Device Use
| Device | Date (since) |
|---|---|
| Home nebulizer (physical object) | 31-Jan-2020 |
| Blood glucose meter (physical object) | 03-Jun-2012 |